Isabella Ciccone, MPH

An evaluation on the long-term treatment profile of sodium oxybate on pediatrics with narcolepsy revealed a safety profile similar to previous adult studies and identified no unexpected safety concerns.

In honor of Purple Day, held on March 26, 2023, get caught up on some of the latest news in epilepsy as the NeurologyLive® team shares some of our data updates.

As a recap from MDA 2023, get caught up on some of the latest news in neuromuscular diseases as the NeurologyLive® team shares some of our data updates.

Differences in baseline characteristics and eligible criteria in presymptomatic infants with spinal muscular atrophy led to differential results on motor and nonmotor clinical outcomes.

Anne Marie Morse, DO, a pediatric neurologist and sleep medicine specialist at Geisinger Medical Center, talked about the challenges that adolescents with narcolepsy face in their social relationships.

Patients with cerebellar ataxia made riskier decisions than controls, suggesting this may be a unique cerebellar cognitive symptom.

In honor of World Sleep Day, held March 17, 2023, get caught up on some of the latest news in sleep disorders as the NeurologyLive® team shares some of our data updates.

Marcus Carstensen, PhD candidate, CTO and co-founder of OptoCeutics in Copenhagen, Denmark, talked about the mechanisms of using noninvasive light technologies for Alzheimer disease treatment.

In honor of Brain Awareness Week, held March 13, 2023, to March 19, 2023, get caught up on some of the latest news in neurology as the NeurologyLive® team shares some of our data updates.

At the 2023 ACTRIMS forum, Omar Al-Louzi, MD, director of the Visual Outcomes Laboratory at Cedars Sinai, talked about investigating the relationship between viral infections and multiple sclerosis using MRIs.

A comparison of narcolepsy cases from the Russian Narcolepsy Network did not differ from data in the European Narcolepsy Network.

In honor of National Sleep Awareness Week, a group of experts in the care of patients with sleep disorders—Wendy Troxel, PhD; Garth Whiteside; Milena Pavlova, MD; Ronald Gavidia, MD, MS; Renee Shellhaas, MD, MS, FAES—shared their perspectives on hot topics of treatment and management in sleep medicine.

Jeffery Neul, MD, PhD, director of the Vanderbilt Kennedy Center, and professor of pediatrics at Vanderbilt University Medical Center, shared his reactions and thoughts to the approval of trofinetide.

In honor of Brain Awareness Week, a group of experts in the care of patients with neurological conditions—Ronald C. Petersen, MD, PhD; Brian Grosberg, MD, FAHS; James Beck, PhD; Michael Levy, MD, PhD; Stanley H. Appel, MD —shared their perspectives on hot topics of treatment and management in neurology.

Published findings showed that narcolepsy has a significant impact on social relationships in adolescents, thus suggesting that structured routine for assessing social health is a vital first step for treatment.

Omar Al-Louzi, MD, director of the Visual Outcomes Laboratory at Cedars Sinai, provided his clinical perspective on role of imaging and viral infections in patients with MS at the 2023 ACTRIMS forum.

Despite higher baseline scores, Expanded Disability Status Scale scores remained stable over time in Black patients treated with ocrelizumab for multiple sclerosis.

The therapy, marketed as Daybue, is the first therapy indicated for Rett syndrome with supporting data from the pivotal phase 3 LAVENDER study.

Literature reveals an inconsistency in sex differences between women and men, among individuals living with dementia with Lewy bodies and their caregivers.

The phase 2b trial investigating SciSparc’s SCI-110 for Tourette syndrome was recently granted approval to proceed by the Israeli Ministry of Health.

Expression of CD16 and activation markers in natural killer and natural killer-T cells may be responsible for the escalating autoimmune activity in NMOSD.

A group of experts in the care of patients with multiple sclerosis—Marisa McGinley, DO; Farrah Mateen, MD, PhD; Laura Piccio, MD, PhD; Robert Zivadinov, MD, PhD; and Bruce Cree, MD, PhD, MAS, FAAN—shared their perspectives on hot topics of treatment and management from the 2023 ACTRIMS Forum.

The international study on genetic testing and counseling, PD GENEration, is currently at the halfway mark of its goal of 15,000 participants.

Rajiv Jain, PhD, post-doctoral associate, department of clinical neurosciences, University of Calgary, talked about his presentation on T-bet+ memory B-cells in multiple sclerosis at the 2023 ACTRIMS Forum.

Newly approved lab-based blood assessing traumatic brain injury rules out the need for CT scan and eliminates wait time at hospitals.

Svetlana P. Eckert, MD, clinical assistant professor of neurology at University at Buffalo, talked about Evusheld as a preventive approach to COVID-19 infections in multiple sclerosis at the 2023 ACTRIMS Forum.

Nine of the 10 participants with NMOSD included in the case series have remained relapse-free after switching to satrlizumab from previous therapy.

Of 2 patient fatalities in the analysis, one was unvaccinated and treated with nonconventional therapies for COVID-19 and the other had a history of deep venous thrombosis and was complicated by pulmonary embolism.

Bruce Cree, MD, PhD, MAS, FAAN, clinical research director of the UCSF Multiple Sclerosis Center provided insight on 2 post-hoc analyses of the N-MOmentum trial for NMOSD that were presented at 2023 ACTRIMS Forum.

Three of 4 patients withdrew from their previous enzyme replacement therapy following treatment with AT845 gene therapy.